DAVID SOURDIVE

About DAVID SOURDIVE

David Sourdive is one of the long-standing figures at Cellectis, where he is a co-founder and has served on the Board of Directors since 2000. He currently holds the position of Executive Vice President CMC & Manufacturing, after previously taking on major responsibilities in corporate development and technical operations. His career reflects a rare blend of scientific depth, industrial execution and strategic leadership, built at the intersection of genome editing, cell therapy and biopharmaceutical development. Over the years, he has helped translate innovative research into industrial programs, with a strong focus on process robustness, scale-up and manufacturing discipline. Sourdive graduated from École Polytechnique, earned a Ph.D. in molecular virology from Institut Pasteur, and completed postdoctoral research at Emory University. He also pursued management training at HEC (Challenge +). Before co-founding Cellectis, he gained substantial experience at the French Ministry of Defense (DGA), where he worked in industrial program management. That background likely contributed to the structured, execution-oriented style that has defined much of his later work in biotechnology. Within Cellectis, he served as Executive Vice President, Corporate Development from 2008 to 2016, and later as Executive Vice President, Technical Operations until July 2019. These roles placed him at the center of strategic development, operational organization and industrial readiness. Today, his CMC & Manufacturing mandate is highly strategic. In advanced therapy and gene-editing companies, CMC leadership is critical because it governs how a promising scientific asset becomes a reproducible, compliant and scalable therapeutic product. Sourdive’s expertise therefore supports one of the most demanding areas of the biopharma value chain: moving complex products from R&D into clinical and, potentially, commercial manufacture. Beyond Cellectis, he also serves as a board member of the Mediterranean Institute for Life Sciences, reflecting continued engagement with the broader life sciences ecosystem. Overall, David Sourdive represents a governance profile shaped by scientific excellence, industrial know-how and long-term commitment to a pioneering French biotechnology company.